ReviewDrugs2019
Upadacitinib: First Approval.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Upadacitinib for refractory Behcet's syndrome: a multi-centre, single-arm trial.Arthritis research & therapy · 2026Trial
- 2-Chloro-5-(trifluoromethyl)aniline-Derived Schiff Base Palladium(II) Complexes: From Molecular Design to Acute Toxicity Assessment.ChemistryOpen · 2026Article
- Real-world evidence on JAK inhibitors in rheumatology practice: comparative safety, efficacy, and outcomes between JAK inhibitors.Clinical rheumatology · 2026Article
- Identification of Pyrrolo [2,3-Molecules (Basel, Switzerland) · 2026Article
- Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial.JAMA oncology · 2026Article
- Revisiting Janus kinases as molecular drug targets for rheumatic diseases.Frontiers in medicine · 2026Review
- Upadacitinib for the treatment of refractory bullous pemphigoid: a case report and literature review.Frontiers in immunology · 2026Review
- Fatal Suicide Attempt with Upadacitinib (RinvoqReports (MDPI) · 2025Article
- Successful Treatment of Comorbid SAPHO Syndrome and Hidradenitis Suppurativa with Upadacitinib.Acta dermato-venereologica · 2025Article
- Sweet syndrome successfully treated with upadacitinib.JAAD case reports · 2025Article
- Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease.Journal of clinical medicine · 2025Review
- Review
- Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis.Journal of ophthalmic & vision research · 2025Article
- Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship.Molecular diversity · 2024Review
- Metabolic effects of upadacitinib in patients with psoriasis and atopic dermatitis.Archives of dermatological research · 2024Article
- Review
- Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Annals of the rheumatic diseases · 2024Review
- Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.Postepy dermatologii i alergologii · 2023Review
- Article
- Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.Signal transduction and targeted therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.
Indexed as
Identifiers
31642025What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.